Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Nov 11:6:103.
doi: 10.1186/1742-4690-6-103.

Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes

Affiliations
Comparative Study

Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes

Tamara Bar-Magen et al. Retrovirology. .

Abstract

Background: Integrase inhibitors are currently being incorporated into highly active antiretroviral therapy (HAART). Due to high HIV variability, integrase inhibitor efficacy must be evaluated against a range of integrase enzymes from different subtypes.

Methods: This study compares the enzymatic activities of HIV-1 integrase from subtypes B and C as well as susceptibility to various integrase inhibitors in vitro. The catalytic activities of both enzymes were analyzed in regard to each of 3' processing and strand transfer activities both in the presence and absence of the integrase inhibitors raltegravir (RAL), elvitegravir (EVG), and MK-2048.

Results: Our results show that integrase function is similar with enzymes of either subtype and that the various integrase strand transfer inhibitors (INSTIs) that were employed possessed similar inhibitory activity against both enzymes.

Conclusion: This suggests that the use of integrase inhibitors against HIV-1 subtype C will result in comparable outcomes to those obtained against subtype B infections.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Purification of recombinant subtype B and C integrase enzymes. N-terminal His tags of the enzymes were removed from purified subtype B and C recombinant proteins by thrombin cleavage. Lane 1, protein ladder (10-250 kDa) (New England Biolabs); INB, subtype B integrase; INC, subtype C integrase.
Figure 2
Figure 2
3' Processing assay. One representative reaction (out of five reactions) is illustrated. Recombinant enzyme was incubated at 37°C with templates (radiolabeled double stranded oligonucleotide INT1/2) for the indicated times up to 120 minutes. The 21-mer substrate and 19-mer 3' processing products are indicated.
Figure 3
Figure 3
Strand transfer assay. One representative reaction (out of five reactions) is depicted. Recombinant integrase enzyme was incubated at 37°C for 3 minutes for the initial 3' processing reaction. T35/SK70, double stranded oligonucleotide substrate, was added and reaction tubes were incubated at 37°C for the indicated times up to 120 minutes. The 21-mer substrate, 19-mer 3' processing, and strand transfer products are indicated.
Figure 4
Figure 4
Disintegration assay. One representative reaction (out of five reactions) is portrayed. Recombinant enzyme was incubated at 37°C for the indicated times up to 120 minutes with disintegration template (radiolabeled oligonucleotide D). Disintegration template and product are indicated. (C-), Negative control lane without integrase enzyme. Top panel, subtype B integrase; bottom panel, subtype C integrase.
Figure 5
Figure 5
Inhibition of 3' processing as a function of increasing RAL concentration. Subtype B and C 3' processing activity (presented as relative percentage) in relation to increasing RAL concentration. This graph was prepared with GraphPad Prism 4.0, the combined result of quantification and analyses of at least 3 independent experiments.
Figure 6
Figure 6
Inhibition of 3' processing as a function of increasing MK-2048 concentration. Subtype B and C 3' processing activity (presented as relative percentage) in relation to increasing MK-2048 concentration. This graph was prepared with GraphPad Prism 4.0, the combined result of quantification and analyses of at least 3 independent experiments.
Figure 7
Figure 7
Inhibition of 3' processing as a function of increasing EVG concentration. Subtype B and C 3' processing activity (presented as relative percentage) in relation to increasing EVG concentration. This graph was prepared with GraphPad Prism 4.0, the combined result of quantification and analyses of at least 3 independent experiments.
Figure 8
Figure 8
Inhibition of strand transfer as a function of increasing RAL concentration. Subtype B and C strand transfer activity (presented as relative percentage) in relation to increasing RAL concentration. This graph was prepared with GraphPad Prism 4.0, the combined result of quantification and analyses of at least 3 independent experiments.
Figure 9
Figure 9
Inhibition of strand transfer as a function of increasing EVG concentration. Subtype B and C strand transfer activity (presented as relative percentage) in relation to increasing EVG concentration. This graph was prepared with GraphPad Prism 4.0, the combined result of quantification and analyses of at least 3 independent experiments.
Figure 10
Figure 10
Inhibition of strand transfer as a function of increasing MK-2048 concentration. Subtype B and C strand transfer activity (presented as relative percentage) in relation to increasing MK-2048 concentration. This graph was prepared with GraphPad Prism 4.0, the combined result of quantification and analyses of at least 3 independent experiments.
Figure 11
Figure 11
Inhibition of disintegration as a function of increasing RAL concentration. Subtype B and C disintegration activity (presented as relative percentage) in reaction to increasing RAL concentration. This graph was prepared with GraphPad Prism 4.0, the combined result of quantification and analyses of 3 independent experiments.
Figure 12
Figure 12
Inhibition of disintegration as a function of increasing MK-2048 concentration. Subtype B and C disintegration activity (presented as relative percentage) in reaction to increasing MK-2048 concentration. This graph was prepared with GraphPad Prism 4.0, the combined result of quantification and analyses of 3 independent experiments.
Figure 13
Figure 13
Inhibition of disintegration as a function of increasing EVG concentration. Subtype B and C disintegration activity (presented as relative percentage) in reaction to increasing EVG concentration. This graph was prepared with GraphPad Prism 4.0, the combined result of quantification and analyses of 3 independent experiments.

References

    1. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261–1269. doi: 10.1016/S0140-6736(07)60597-2. - DOI - PubMed
    1. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M, Ikeda S, Matsuoka M. Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137) J Virol. 2008;82:764–774. doi: 10.1128/JVI.01534-07. - DOI - PMC - PubMed
    1. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY. BENCHMRK Study Teams. Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. N Engl J Med. 2008;359:355–365. doi: 10.1056/NEJMoa0708978. - DOI - PubMed
    1. Briz V, Garrido C, Poveda E, Morello J, Barreiro P, de Mendoza C, Soriano V. Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res Hum Retroviruses. 2009;25:225–227. doi: 10.1089/aid.2008.0222. - DOI - PubMed
    1. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006;20:W13–23. doi: 10.1097/01.aids.0000247564.73009.bc. - DOI - PubMed

Publication types

LinkOut - more resources